Get the Stockscreener App
1.601
3.03%
-0.049
Rani Therapeutics Holdings Inc stock is traded at $1.601, with a volume of 1.50M.
It is down -3.03% in the last 24 hours and up +11.89% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
See More
Previous Close:
$1.65
Open:
$1.6
24h Volume:
1.50M
Relative Volume:
1.62
Market Cap:
$54.96M
Revenue:
$3.04M
Net Income/Loss:
$-33.97M
P/E Ratio:
-1.2038
EPS:
-1.33
Net Cash Flow:
$-52.47M
1W Performance:
+15.11%
1M Performance:
+11.89%
6M Performance:
-34.16%
1Y Performance:
-57.78%
1-Day Range:
$1.50
$1.65
1-Week Range:
$1.35
$1.82
52-Week Range:
$1.24
$8.75
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.595 | 54.96M | 3.04M | -33.97M | -52.47M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.57 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.64 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.31 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.20 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.67 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Was there any good news for Rani Therapeutics Holdings Inc (RANI) stock in the last session? - US Post News
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt? - Simply Wall St
Market cap of Tantech Holdings Ltd [TANH] reaches 1.11M – now what? - The DBT News
Rani Therapeutics Holdings Inc (RANI Stock: A Sea of Opportunity - The InvestChronicle
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Rani Therapeutics Discloses Progress in Oral Obesity Treatment; Shares Surge Premarket - Marketscreener.com
Rani Therapeutics (NASDAQ:RANI) Shares Up 0.7%Still a Buy? - MarketBeat
Rani Therapeutics reports positive obesity treatment study - Investing.com India
Rani Therapeutics reports positive obesity treatment study By Investing.com - Investing.com South Africa
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery Of Semaglutide Via Ranipill HC - Marketscreener.com
Rani Therapeutics Announces Preclinical Data Demonstrating - GlobeNewswire
Oral Wegovy Alternative Shows Breakthrough Results: Rani's Pill Matches Injectable Efficacy - StockTitan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Consensus Target Price from Analysts - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Consensus PT from Brokerages - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Target Price from Brokerages - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Shares Purchased by Geode Capital Management LLC - Defense World
Rani Therapeutics stock hits 52-week low at $1.29 - Investing.com India
Rani Therapeutics stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Shares Acquired by Stifel Financial Corp - Defense World
Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71 - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average PT from Brokerages - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.32 - Investing.com
Insider Buying: Kate Mckinley Acquires Shares in Rani Therapeuti - GuruFocus.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Kate Mckinley Acquires 17,960 Shares - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.85 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.85 - Investing.com India
CEO Talat Imran Acquires Additional Shares of Rani Therapeutics Holdings Inc (RANI) - GuruFocus.com
Rani Therapeutics stock hits 52-week low at $1.94 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.94 - Investing.com India
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Target Price from Analysts - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $11.71 - MarketBeat
What is Zacks Small Cap’s Forecast for RANI FY2024 Earnings? - Defense World
What is Zacks Small Cap's Forecast for RANI FY2024 Earnings? - MarketBeat
RANI: Third Quarter Update - MSN
Rani Therapeutics' (RANI) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rani Therapeutics Advances in Biotherapeutics Market - TipRanks
Rani Therapeutics Holdings Inc (RANI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics Slashes Q3 Loss by 31%, Secures $20M Funding for GLP-1 Development | RANI Stock News - StockTitan
Rani Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) PT at $11.71 - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short Interest - MarketBeat
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rani Therapeutics Holdings Inc Stock (RANI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Imran Talat | Chief Executive Officer |
Dec 09 '24 |
Buy |
1.94 |
10,296 |
19,974 |
494,751 |
| South Cone Investments Limited | 10% Owner |
Oct 15 '24 |
Sale |
2.65 |
3,829,360 |
10,141,674 |
8,302,194 |
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):